市場調查報告書
商品編碼
1271794
臨床試驗市場 - 按階段、研究設計、治療領域和預測,2023-2032 年Clinical Trials Market - By Phases, By Study Design, By Therapeutic Area & Forecast, 2023 - 2032 |
由於亞太地區臨床試驗數量的增加,預計到 2032 年全球臨床試驗市場規模將達到高估值。
不斷增加的慢性病負擔增加了該地區對臨床試驗的需求。 據世界衛生組織稱,印度估計有 2500 萬人處於糖尿病前期。
行業產品創新的加劇,進一步促進了市場的擴大。 例如,2022 年 10 月,領先的臨床研究機構 ICON plc 宣布,它已被美國生物醫學高級研究與開發機構選中,對一種炭疽疫苗進行臨床試驗。
整個臨床試驗行業根據階段、研究設計、治療領域和地理區域進行細分。
根據階段,I 期臨床試驗市場份額預計到 2032 年將顯著增長。 I 期臨床試驗結果為進一步的藥物開發提供了背景。 這些試驗著眼於副作用、安全性、患者的適當劑量等。 此外,由於研究方法的最新進展,I 期臨床試驗的高效性對該領域的增長做出了積極貢獻。
根據研究設計,觀察性研究的市場規模將在 2022 年達到 110 億美元以上。 與乾預措施和擴大可及性相比,觀察性研究具有更高的成本效益,這將有利於擴大該領域。 這些研究是快速的,並為研究人員提供了對現實世界中正在發生的事情的洞察力。 此外,它在調查罕見結果和不常見副作用方面的作用將推動其在未來十年的採用。
按治療領域劃分,到 2032 年,腫瘤臨床試驗市場銷售額預計將顯著增長。 癌症患者的增加以及隨之而來的政府對癌症研究投資的增加有利於該行業的發展。 例如,2023 年 1 月,加拿大政府宣布加拿大衛生研究院 (CIHR) 投資超過 2300 萬美元,成立加拿大兒童癌症研究聯盟。 此類研發計劃的增加將增加未來幾年對臨床試驗的需求。
到 2032 年,歐洲臨床試驗行業的價值預計將超過 230 億美元。 臨床研究數量的增加和政府對臨床研究的支持將有助於該地區的擴張。 事實上,該地區有許多提供高質量臨床研究的協會,例如歐洲 CRO 聯合會 (EUCROF)。 此外,慢性病患病率的上升進一步增加了該地區對臨床研究的需求。
Global Clinical Trials Market size is anticipated to record an appreciable valuation by 2032, owing to the increasing prospects for performing clinical trials in the Asia Pacific. The consistent rise in the burden of chronic disorders has accentuated the need for clinical trials in the region. As per the WHO, an estimated 25 million people are prediabetic in India.
Escalating product innovations in the industry are further contributing to market expansion. For instance, in October 2022, ICON plc, a leading clinical research organization announced its selection by US Biomedical Advanced Research and Development Authority for conducting an anthrax vaccine clinical trial.
The overall clinical trials industry is segmented in terms of phases, study design, therapeutic area, and region.
Based on phases, the clinical trials market share from the phase I segment is expected to grow considerably through 2032. Phase I clinical trial results serve as the background for further progress in drug development. These studies examine the side effects, safety, and appropriate dosage level for patients. Furthermore, high efficacy of phase I clinical trials due to recent advancements in research methodologies is positively contributing to segment growth.
Based on the study design, the market size from the observational study segment recorded more than USD 11 billion in 2022. The cost-effectiveness of observational studies over their interventional and expanded access counterparts will favor segment expansion. These studies are quick and provide researchers with insights into what occurs in real-life situations. Moreover, their usefulness in investigating rare outcomes and unusual side effects will boost their adoption in the next ten years.
In terms of therapeutic area, the clinical trials market revenue from the oncology segment is poised to depict significant growth through 2032. Increasing incidences of cancer and the subsequent rise in investments by the government in cancer research are working in favor of segment growth. To illustrate, in January 2023, the government of Canada announced an investment of more than USD 23 million from the Canadian Institutes of Health Research (CIHR) for the establishment of the Canadian Pediatric Cancer Consortium for pediatric cancer research. Increasing R&D initiatives such as these will augment the demand for clinical trials in the forthcoming years.
Europe clinical trials industry is expected to be valued at over USD 23 billion by 2032. Rising number of clinical studies, along with favorable government support for clinical research, may contribute to regional expansion. In fact, the region is also home to many associations, such as the European CRO Federation (EUCROF), that provide high-quality clinical research. Moreover, the growing prevalence of chronic diseases has further increased the need for clinical research in the region.